In summary, therapeutically blocking hPGDS and PGD2 biosynthesis could be beneficial to delay the onset of allergic asthma, reduce eosinophilic and Th2 type inflammation, alleviate symptoms including allergic rhinitis and cough as well as reduce airway remodelling. This evidence concerns the gene HPGDS and allergic asthma.